One of the sadder stories in RNAi Therapeutics history is the many years lost in the commercial development of drugs based on DNA-directed R...

It is official now : Novartis will not exercise its $100M option to broadly license Alnylam’s RNAi trigger IP. This must come as a shock to ...

After deciding to focus on the use of so-called ‘self-delivering’ siRNAs (‘sd-rxRNA’) for dermatology and ophthalmology applications, RXi Ph...

Tekmira’s ambition to grow a substantial clinical pipeline suffered a setback when it announced today that the IND for its candidate for th...

My guess: Pfizer or Novartis. I have just returned from a vacation on the beautiful island of Taiwan that also allowed me, finally away fr...

As I am about to do some traveling over the next couple of weeks and won’t be able to monitor the markets closely, part of my preparations i...

I was quite amused today, while driving a car on Borneo, the local radio report the headline ‘US scientists said that they are ready to star...